Medikamentöse Therapie des Pankreaskarzinoms-Reference-Cited by-同舟云学术

Medikamentöse Therapie des Pankreaskarzinoms

Published:2020-01-29 Issue:2 Volume:61 Page:226-232
ISSN:0020-9554
Container-title:Der Internist
language:de
Short-container-title:Internist

Author:

Feldmann Georg

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00108-020-00750-y.pdf

Reference49 articles.

1. Ansari D, Ohlsson H, Althini C et al (2019) The hippo signaling pathway in pancreatic cancer. Anticancer Res 39:3317–3321

2. Beatty GL, O’hara MH, Lacey SF et al (2018) Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155:29–32

3. Bisht S, Brossart P, Feldmann G (2018) Current therapeutic options for pancreatic ductal adenocarcinoma. Oncol Res Treat 41:590–594

4. Bisht S, Brossart P, Maitra A et al (2010) Agents targeting the hedgehog pathway for pancreatic cancer treatment. Curr Opin Investig Drugs 11:1387–1398

5. Bisht S, Feldmann G (2018) Novel targets in pancreatic cancer therapy—current status and ongoing translational efforts. Oncol Res Treat 41:596–602

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer;International Journal of Molecular Sciences;2024-06-06

2. A novel derivative of Genistein inhibits proliferation of ovarian cancer HO-8910 cells by regulating reactive oxygen species*;Oncology and Translational Medicine;2022-12